UC Davis Health Clinical Studies

Experimental Inotuzumab Ozogamicin and Chemotherapy for Types of Leukemia

Volunteer for research at UC Davis and contribute to discoveries that may improve health care for you, your family, and your community!

The goals of this study are to study: · For High-Risk B-ALL (HR B-ALL): Whether adding experimental inotuzumab ozogamicin (InO) to standard chemotherapy maintains or improves outcomes. · For High-Risk B-ALL (HR B-ALL): Whether treating both males and females for 2 years from the start of Interim Maintenance maintains outcomes for males who have previously been treated for 3 years from the start of Interim Maintenance. · For High-Risk Favorable (HR-Fav) : To describe outcomes for patients when treated with one phase of Interim Maintenance instead of two. Also, when treating both males and females with the same duration of chemotherapy (2 years from the start of Interim Maintenance)

Drug study, Phase 3
Any, age 1 to 24 years old

Experimental Erdafitinib for Relapsed/Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorder

Volunteer for research at UC Davis and contribute to discoveries that may improve health care for you, your family, and your community!

This is a Phase 2 study of an experimental drug called JNJ-42756493 (erdafitinib). In a Phase 2 study, the goal is to find out what effects, good and/or bad, a drug has on your tumor or type of cancer. We are using JNJ-42756493 (erdafitinib) in this study because it has been shown to block the growth of cancer cells with changes (mutations) in the FGFR1/2/3/4 genes. These mutations help cancer cells grow in test tubes and in animals. You are eligible for this study because your tumor was found to have a mutation in one of these genes. JNJ-42756493 (erdafitinib) is considered a study drug in the treatment of your tumor or type of cancer, we do not know if it will work against the type of tumor you have. A Phase 1 study of JNJ-42756493 (erdafitinib) has been completed in adults with cancer. In the Phase 1 study, researchers determined the dose of JNJ-42756493 (erdafitinib) can be given without too many side effects. This study will be the first time that JNJ-42756494 (erdafitinib) is given to children. The dose used in this study will be based on the dose used in adults. If you have bad side effects, your dose may be decreased. The goals of this study are: The main goal is to test any good and bad effects of the study drug JNJ-42756493 (erdafitinib) on your tumor. A second goal of the study is to evaluate side effects that might be caused by JNJ-42756493 (erdafitinib). Another goal is to learn more about the pharmacology (how your body handles the drug) of JNJ-42756493 (erdafitinib)

Drug study, Phase 2
Any, age 1 to 21 years old

Testing an Experimental Anti-Cancer Drug M3814 for Relapsed or Refractory Acute Myeloid Leukemia

Volunteer for research at UC Davis and contribute to discoveries that may improve health care for you, your family, and your community!

This study is being done to answer the following question: Can we lower the chance of your acute myeloid leukemia growing or spreading by adding an experimental new drug to the usual combination of drugs? We are doing this study because we want to find out if this approach is better or worse than the usual approach for your acute myeloid leukemia. The usual approach is defined as care most people get for acute myeloid leukemia.

Drug study, Phase 1
Any, age 18 years or older

An Experimental Combination Study of S1803, Daratumumab/rHuPh20 +/- Lenalidomide for Multiple Myeloma (MM)

Volunteer for research at UC Davis and contribute to discoveries that may improve health care for you, your family, and your community!

This study is being done to answer the following questions: 1. Will adding the experimetnal drug daratumumab/rHuPH20 to the usual maintenance treatment help multiple myeloma patients survive longer? 2. For patients who have no evidence of multiple myeloma in their bone marrow, should maintenance therapy be stopped after 2 years? We are doing this study because we want to find out if this approach is better or worse than the usual approach for your multiple myeloma. The usual approach is defined as care most people get for multiple myeloma. The usual approach for patients who are not in a study is treatment with an FDA approved multiple myeloma drug (such as lenalidomide) after stem cell transplant.

Drug study, Phase 3
Any, age 18 to 75 years old
Loading